Lineage Cell Therapeutics Inc (LCTX) FinancialsLCTXLineage Cell Therapeutics Inc

Evaluating the bottom line, Lineage Cell Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -834.71%, while the net margin is 144.43%. These profitability ratios, combined with a Return on Equity (ROE) of -59.03%, provide a clear picture of how effectively LCTX converts its operational activities into shareholder value.

In the context of the broader market, LCTX competes directly with industry leaders such as GLSI and CABA. With a market capitalization of $260.50M, it holds a leading position in the sector. When comparing efficiency, LCTX's gross margin of 100.00% stands against GLSI's N/A and CABA's N/A. Such benchmarking helps identify whether Lineage Cell Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 100% in Q2 2026, indicating strong profitability. However, it has faced challenges with revenue, reporting a decline of 61.4% year-over-year in Q2 2026, with revenues of only $1.07 million.